Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, it has had a relatively poor prognosis, including low five-year overall survival rates. Chemotherapy…
CAR T-cell therapies, such as Gilead / Kite Pharma’s Yescarta and Janssen’s Carvykti, have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and patients…
The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL…
The sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are frequently prescribed for type 2 diabetes (T2D). These classes, along with glucose-…
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment duration. The availability of premium-priced branded agents prescribed…
The type 2 diabetes (T2D) therapy market will expand over the first half of the 2021-2031 forecast period. This increase will be partly fueled by a rich pipeline of novel agents; emerging…
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, it has had a relatively poor prognosis, including low five-year overall survival rates. Chemotherapy…
Multiple myeloma is a hematologic malignancy that arises from an overproduction of plasma cells in the bone marrow. In patients with active disease, immunomodulatory drugs (e.g., Revlimid, Pomalyst…
The chronic myeloid leukemia (CML) drug-treatment market is dominated by BCR-ABL tyrosine kinase inhibitors, notably imatinib (Novartis’s Gleevec; generics); these agents enable many CML patients…
The acute lymphoblastic leukemia (ALL) therapy market is growing steadily, fueled by innovations in the treatment paradigm. The availability of premium-priced branded agents prescribed in multidrug…
Relapsed / refractory diffuse large B-cell lymphoma (R/R DLBCL) is an aggressive disease with significant unmet need. The treatment landscape has evolved since the approval of various novel…
Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective…
Male hypogonadism (low testosterone [low T]) is a condition characterized by impaired spermatogenesis and low serum testosterone. The majority of cases are caused by low T driven by age or…
Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Therefore, it is unsurprising that insulins…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…